Skip to content

Comparison of Continuous Epidural Infusion of Bupivacaine and Fentanyl versus Patient Controlled Analgesia techniques for Labor Analgesia

Comparison of severity of pain in continuous Epidural Infusion of Bupivacaine and Fentanyl versus Patient Controlled Analgesia techniques for Labor Analgesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014121610765N6
Enrollment
60
Registered
2016-07-08
Start date
2015-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Labor pain. Condition 2: delivery. Single spontaneous delivery Multiple delivery

Interventions

Intervention 1: Patients of group one (group receiving continued infusion, 30 patients) will receive the blobs dose of solution that contain bupivacaine 0.125 plus fentanil 3µg/ml (total volume of 1
Treatment - Drugs
Patients of group one (group receiving continued infusion, 30 patients) will receive the blobs dose of solution that contain bupivacaine 0.125 plus fentanil 3µg/ml (total volume of 10 ml) through ca
Patients of group two (30 patients)will receive the blobs dose of 10 ml from solution that contain bupivacaine 125 mg (26 ml bupivacaeine 0.5% and 100 µg fentanyl in 100 ml normal saline through cat

Sponsors

Vice chancellor for reaserch, Tabriz University of Medical Scienses
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Parturients with 18-40 years of old; parturients with ASA Class I or II; consenting to be including to the study; women with active labor and vertex presentation Exclusion criteria: Parturients with ASA Class III or higher; cardiovascular diseases; respiratory diseases; contraindication for epidural ; presentation other than vertex; patients with chronic pain and use of analgesics; diabetics

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: every 30 minutes from drug adminstration until delivery. Method of measurement: visual analog scale.

Secondary

MeasureTime frame
Motor block. Timepoint: every 30 minute from drug adminstration to delivery. Method of measurement: Modified Bromage scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSousan Rasouli

Reaserch center, Tabriz University of Medical Scienses

Rasooli_s@yahoo.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026